

1 **Title:** A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on
2 Repeat Infection.

3
4 **Authors:**

5 Kojima N¹; Shrestha NK²; and Klausner JD³

6
7 ¹ Department of Medicine, University of California Los Angeles, Los Angeles, 90095

8 ² Department of Infectious Diseases, Cleveland Clinic, Cleveland, 44195

9 ³ Departments of Medicine and Population and Public Health Sciences, Keck School of
10 Medicine, University Southern California, Los Angeles, 90032

11

12

13

14

15

16

17

18

19

20

21 **Corresponding Author Contact Information:**

22 Department of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA

23 90095. Email: nkojima@ucla.edu

24

25 **Abstract**

26 **Introduction:** We systematically reviewed studies to estimate the risk of SARS-CoV-2
27 reinfection among those previously infected with SARS-CoV-2.

28 **Methods:** For this systematic review, we searched scientific publications on PubMed
29 and, the pre-print server, MedRxiv through August 18, 2021. Eligible studies were
30 retrieved on August 18, 2021. We used the following search term on PubMed:

31 (((("Cohort Studies"[Majr]) AND ("COVID-19"[Mesh] OR "SARS-CoV-2"[Mesh])) OR
32 "Reinfection"[Majr]) OR "Reinfection"[Mesh]. We used the following search term on
33 MedRxiv: "Cohort Studies" AND "COVID-19" OR "SARS-CoV-2" AND "Reinfection".

34 The search terms were broad to encompass all possibilities for applicable studies.

35 There were no restrictions on the date of publication. Studies that did not describe
36 cohorts with estimates of the risk of SARS-CoV-2 reinfection among those with previous
37 infection were excluded. Studies that included vaccinated participants were either
38 excluded or limited to sub-groups of non-vaccinated individuals. To identify relevant
39 studies with appropriate control groups, we developed the following criteria for studies
40 to be included in the systematic analysis: (1) baseline polymerase chain reaction (PCR)
41 testing, (2) a negative comparison group, (3) longitudinal follow-up, (4) a cohort of
42 human participants, i.e., not a case report or case series, and (5) outcome determined
43 by PCR. The review was conducted following PRISMA guidelines. We assessed for
44 selection, information, and analysis bias, per PRISMA guidelines.

45 **Results:** We identified 1,392 reports. Of those, 10 studies were eligible for our
46 systematic review. The weighted average risk reduction against reinfection was 90.4%

47 with a standard deviation of 7.7%. Protection against SARS-CoV-2 reinfection was
48 observed for up to 10 months. Studies had potential information, selection, and analysis
49 biases.

50 **Conclusions:** The protective effect of prior SARS-CoV-2 infection on re-infection is
51 high and similar to the protective effect of vaccination. More research is needed to
52 characterize the duration of protection and the impact of different SARS-CoV-2 variants.

53 **MAIN TEXT**

54 **Introduction**

55 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent
56 of coronavirus disease 2019 (COVID-19), is highly infectious and continues to cause
57 substantial morbidity and mortality (Dong et al., 2020; Jin et al., 2020). Prior to the
58 development of highly safe and effective vaccines for SARS-CoV-2 infection, scientists
59 reported that a history of COVID-19 was associated with reduced risk of SARS-CoV-2
60 reinfection (Addetia et al., 2020). Virus-induced immunity has been described in many
61 infections and is responsible for the decline of epidemic spread associated with
62 exhaustion of the susceptible population (Rouse & Sehrawat, 2010). However, the
63 duration and degree of the protective effect of SARS-CoV-2s-induced immunity is poorly
64 studied.

65
66 Prior epidemiologic studies have found that individuals who are SARS-CoV-2 antibody-
67 positive are protected against reinfection (Abu-Raddad et al., 2021; Harvey et al., 2021;
68 Jeffery-Smith et al., 2021). Furthermore, investigators have reported that even those
69 with prior SARS-CoV-2 infection *who lacked detectable antibodies* were at 80% lower
70 risk of reinfection than people who were SARS-CoV-2 naïve (Breathnach et al., 2021).
71 One retrospective study that analyzed test results among nearly 10,000 individuals with
72 prior SARS-CoV-2 infection found that only 0.7% became reinfected with SARS-CoV-2
73 (Qureshi et al., 2021).

74

75 Other studies have also described reduced risk of infection, morbidity, and mortality
76 among those with prior COVID-19. A study conducted in Austria found that the
77 frequency of hospitalization and death due to a SARS-CoV-2 reinfection was 5 out of
78 14,840 (0.03%) and 1 out of 14,840 (0.01%), respectively (Pilz et al., 2021).

79
80 A history of COVID-19 may be as protective against reinfection as vaccination for
81 SARS-CoV-2. A study investigating the frequency of repeat infection among laboratory
82 personnel undergoing daily testing found no difference in SARS-CoV-2 infection rates
83 between those with prior COVID-19 versus those vaccinated for SARS-CoV-2 infection
84 (Kojima et al., 2021). Thompson et al. also reported that the decrease in risk of SARS-
85 CoV-2 reinfection among those with prior infection was similar in magnitude to the
86 relative risk reduction against SARS-CoV-2 infection among those who were vaccinated
87 (Thompson et al., 2021). In a longitudinal study conducted among employees at the
88 Cleveland Clinic, vaccination was not found to be associated with a lower risk of SARS-
89 CoV-2 infection among people with prior COVID-19 (Shrestha et al., 2021).

90
91 Despite the availability of safe and effective vaccines, rates of SARS-CoV-2 infection
92 are again increasing, especially among those without immunity (Christie et al., 2021).
93 We aimed to determine the protective effect of previous infection among those who
94 have not been also vaccinated against SARS-CoV-2. We systematically reviewed
95 published longitudinal studies to estimate the risk of SARS-CoV-2 reinfection among
96 those previously infected with SARS-CoV-2.

97

98 **Methods**

99 For this systematic review, we searched scientific publications on PubMed and the pre-
100 print server, MedRxiv. through August 18, 2021. Eligible studies were retrieved on
101 August 18, 2021. We used the following search term on PubMed: (((("Cohort
102 Studies"[Majr]) AND ("COVID-19"[Mesh] OR "SARS-CoV-2"[Mesh])) OR
103 "Reinfection"[Majr]) OR "Reinfection"[Mesh]. We used the following search term on
104 MedRxiv: "Cohort Studies" AND "COVID-19" OR "SARS-CoV-2" AND "Reinfection".
105 The search terms were broad to encompass all possibilities for applicable studies.
106 There were no restrictions on the date of publication. Studies that did not describe
107 cohorts with estimates of the risk of SARS-CoV-2 reinfection among those with previous
108 infection were excluded. Studies that included vaccinated participants were either
109 excluded or limited to sub-groups of non-vaccinated individuals.

110
111 To identify relevant studies with appropriate control groups, we developed the following
112 criteria for studies to be included in the systematic analysis: (1) baseline polymerase
113 chain reaction (PCR) testing, (2) a negative comparison group, (3) longitudinal follow-up,
114 (4) a cohort of human participants, i.e., not a case report or case series, and (5)
115 outcome determined by PCR.

116
117 The review was conducted following PRISMA guidelines (Page et al., 2021). Two
118 reviewers identified studies for the review. One reviewer collected data from each report
119 and the other reviewer independently checked the work. Abstracts were reviewed and
120 ineligible studies were not included. We reviewed selected reports to extract the

121 following information: Author, year of publication, study cohort, reinfection risk, and
122 follow-up time in person-years, when available. We assessed for selection, information,
123 and analysis bias, per PRISMA guidelines. Due to the heterogeneity of the studies
124 reviewed, sensitivity analyses and a meta-analysis was not attempted. Studies with
125 outcomes were listed in a table.

126

127 There was no funding for this study.

128

129 **Results**

130 We identified 1,392 reports (Figure). Of those reports, 10 studies met the above criteria
131 from 6 different countries. The total population in the 10 studies included 9,930,470
132 individuals with a median observation period that ranged from one to 10.3 months.

133

134 We found that the relative decreased risk of SARS-CoV-2 reinfection ranged between
135 80.5 to 100% compared to those without prior infection (Table). The weighted average
136 risk reduction against reinfection was 90.4%, with a standard deviation of 7.7%.

137

138 The studies conducted by Goldberg et al., Hansen et al., Pilz et al., and Vitale et al., had
139 cohorts compiled from national databases, which may have generated a selection bias
140 towards people who had access to SARS-CoV-2 testing and were registered (Goldberg
141 et al., 2021; Hansen et al., 2021; Pilz et al., 2021; Vitale et al., 2021). The study
142 conducted by Hall et al. followed a cohort of 30,625 participants (Hall et al., 2021). In
143 their study 51 participants withdrew and 4,913 participants were excluded because they

144 did not have linked data for SARS-CoV-2 testing. That may have biased their study
145 against people who did not have follow up testing, i.e., information and analysis bias.
146 The study conducted by Letizia et al. studied young and healthy adults in the United
147 States Marines who were undergoing basic training, and the housing conditions and
148 interactions of individuals in that setting would not be readily extrapolated to the
149 average population (Letizia et al., 2021). The study conducted by Rennert et al. studied
150 university students that are younger and healthier than the average population (Rennert
151 & McMahan, 2021). The study conducted by Shrestha et al. included younger and
152 relatively healthier people, and since the study was done entirely after vaccines became
153 available, there was also likely selection bias due to differential participation among
154 those who decided not to get vaccinated (Shrestha et al., 2021).

155
156 The studies conducted by Hall et al., Rennert et al., and Sheehan et al., included follow-
157 up that extended into the period when vaccines became available, and since
158 vaccination was not controlled for, it is likely that vaccination among some subjects in
159 the previously uninfected groups would have resulted in information bias resulting in an
160 underestimation or overestimation of the effect size (Hall et al., 2021; Rennert &
161 McMahan, 2021; Sheehan et al., 2021).

162

163 **Discussion**

164 We systematically reviewed published longitudinal studies of SARS-CoV-2 reinfection
165 with PCR confirmed initial and repeat infections. We found that the weighted average
166 risk reduction against reinfection was 90.4%. Protection was observed up to 10 months.

167 People with prior COVID-19 had a similar and durable level of protection when
168 compared to those vaccinated against SARS-CoV-2 (Kojima et al., 2021; Stephens &
169 McElrath, 2020).

170
171 In our systematic review, protection against SARS-CoV-2 reinfection was observed in
172 up to 10 months following initial infection. It is not clear how long natural protection after
173 infection will last. Biological studies have found persistent reservoirs of immunological
174 active and antibody producing cells for up to 10 months or longer (Cohen et al., 2021).

175
176 The studies were conducted in 6 different countries. The studies ranged from
177 participants that were younger than the national average (Letizia et al., 2021; Rennert &
178 McMahan, 2021), as well as populations that were older than the national average
179 (Vitale et al., 2021). Some studies followed participants at a national level (Goldberg et
180 al., 2021; Hansen et al., 2021; Pilz et al., 2021), whereas other studies more closely
181 followed cohorts (Letizia et al., 2021; Rennert & McMahan, 2021). While methodologies
182 of studies differed, all reviewed studies consistently found decreased risk of reinfection
183 among people with prior SARS-CoV-2 infection.

184
185 A recent United States Centers of Disease Control and Prevention (CDC) investigation
186 conducted in Kentucky among persons with prior COVID-19 found that vaccination
187 enhanced the protection of those with prior infection (Cavanaugh et al., 2021). In the
188 CDC study, lack of vaccination after infection was associated with an increased odds of
189 repeat SARS-CoV-2 infection, although the absolute increased risk of re-infection was

190 very low. The study may have been biased due to different risk behaviors of the cases
191 and controls. The study was not controlled for adherence with pandemic precautions
192 (masking and social distancing), which would have been expected to have been
193 different in the cases and controls.

194
195 Our study had several limitations. Our review was limited to studies with PCR
196 confirmation of infection and re-infection. Multiple other studies, however, using SARS-
197 CoV-2 antibody status as a measure of infection have similar results (Abu-Raddad et al.,
198 2021; Harvey et al., 2021; A Leidi et al., 2021; A. Leidi et al., 2021). Our systematic
199 review utilized some studies published on MedRxiv, a pre-print server. While MedRxiv
200 had been helpful during the COVID-19 pandemic due to the rapid ability to disseminate
201 information to colleagues, studies that were accessed on the site were not peer-
202 reviewed. Furthermore, many of the studies cannot be replicated because they occurred
203 in settings prior to the availability of vaccination against SARS-CoV-2 among people
204 with history of infection.

205
206 Many of the studies including in our review followed people infected with SARS-CoV-2
207 earlier in the pandemic when infection was most likely with the original wildtype strain of
208 SARS-CoV-2 before the development of variant strains. Therefore, our findings may
209 differ in the current context of infections with exposure to variants that differ from the
210 original infecting variant.

211

212 However a recent pre-print from a study conducted in the United Kingdom found among
213 persons infected during a period of nearly exclusive Delta SARS-CoV-2 transmission,
214 those fully vaccinated with BNT162b2 and ChAd0x1 (had similar levels of protection
215 (82% and 67%, respectively) as those with previous infection (73%) (Pouwels; et al.,
216 2021). Additionally, in a recent retrospective cohort study that was conducted in Israel
217 which compared rates of SARS-CoV-2 infection or reinfection with the Delta variant
218 among SARS-CoV-2-naïve individuals who received the BNT162b2 vaccine to people
219 who had recovered from COVID-19, found that vaccinated, but SARS-CoV-2-naïve
220 people, had an increased risk of infection with the Delta variant when compared to
221 people who had recovered from COVID-19 (Gazit et al., 2021). This association was
222 statistically significant in two models that either matched to the time of the first event
223 (13.1-fold increased risk) or did not match to time of first event (6.0-fold increased risk).

224

225 **Implications**

226 Our findings suggest that persons with prior COVID-19 are protected against SARS-
227 CoV-2 reinfection. While protection has been observed in up to 10 months after initial
228 infection, it is unclear how long the protection will last. Given the recency of new
229 circulating variants like Delta, the protective effect of a previous infection with one
230 variant and exposure to a different variant are uncertain. However, recent studies during
231 the period of transmission of the Delta variant are promising.

232

233 **Conclusions**

234 There is consistent epidemiologic evidence that prior SARS-CoV-2 infection provides
235 substantial immunity to repeat SARS-CoV-2 infection. Prior SARS-CoV-2 infections
236 provide similar protection when compared to vaccination for SARS-CoV-2. Longer
237 follow-up studies are needed to determine how long protection lasts for natural immunity,
238 especially among higher risk groups such as those with chronic medical conditions and
239 those that are immunocompromised. More research is needed to investigate whether
240 disease severity changes the risk of repeat infection. Finally, more research is needed
241 to determine how much protection persists against emerging variants, like the Delta
242 variant of SARS-CoV-2.

243

244 **Declarations**

245 *Declaration of competing interests*

246 NK has received consulting fees from Curative Inc. JDK serves as Medical Director of
247 Curative Inc.

248

249 *Funding*

250 None

251

252 *Acknowledgements*

253 None

254 **References**

- 255 Abu-Raddad, L. J., Chemaitelly, H., Coyle, P., Malek, J. A., Ahmed, A. A., Mohamoud,
256 Y. A., Younuskunju, S., Ayoub, H. H., Al Kanaani, Z., Al Kuwari, E., Butt, A. A.,
257 Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul Rahim, H. F.,
258 Nasrallah, G. K., Yassine, H. M., Al Kuwari, M. G., Al Romaihi, H. E., Al-Thani,
259 M. H., Al Khal, A., & Bertollini, R. (2021). SARS-CoV-2 antibody-positivity
260 protects against reinfection for at least seven months with 95% efficacy.
261 *EClinicalMedicine*, 35, 100861. <https://doi.org/10.1016/j.eclinm.2021.100861>
- 262 Addetia, A., Crawford, K. H. D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M. L.,
263 Jerome, K. R., Bloom, J. D., & Greninger, A. L. (2020). Neutralizing Antibodies
264 Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel
265 Outbreak with a High Attack Rate. *J Clin Microbiol*, 58(11).
266 <https://doi.org/10.1128/JCM.02107-20>
- 267 Breathnach, A. S., Duncan, C. J. A., Bouzidi, K. E., Hanrath, A. T., Payne, B. A. I.,
268 Randell, P. A., Habibi, M. S., Riley, P. A., Planche, T. D., Busby, J. S.,
269 Sudhanva, M., Pallett, S. J. C., & Kelleher, W. P. (2021). Prior COVID-19
270 protects against reinfection, even in the absence of detectable antibodies. *J*
271 *Infect*, 83(2), 237-279. <https://doi.org/10.1016/j.jinf.2021.05.024>
- 272 Cavanaugh, A., Spicer, K., Thoroughman, D., Glick, C., & Winter, K. (2021). Reduced
273 Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky,
274 May–June 2021. *MMWR Morb Mortal Wkly Rep*.
275 <https://doi.org/10.15585/mmwr.mm7032e1>

- 276 Christie, A., Brooks, J. T., Hicks, L. A., Sauber-Schatz, E. K., Yoder, J. S., Honein, M.
277 A., & Team, C. C.-R. (2021). Guidance for Implementing COVID-19 Prevention
278 Strategies in the Context of Varying Community Transmission Levels and
279 Vaccination Coverage. *MMWR Morb Mortal Wkly Rep*, 70(30), 1044-1047.
280 <https://doi.org/10.15585/mmwr.mm7030e2>
- 281 Cohen, K. W., Linderman, S. L., Moodie, Z., Czartoski, J., Lai, L., Mantus, G., Norwood,
282 C., Nyhoff, L. E., Edara, V. V., Floyd, K., De Rosa, S. C., Ahmed, H., Whaley, R.,
283 Patel, S. N., Prigmore, B., Lemos, M. P., Davis, C. W., Furth, S., O'Keefe, J. B.,
284 Gharpure, M. P., Gunisetty, S., Stephens, K., Antia, R., Zarnitsyna, V. I.,
285 Stephens, D. S., Edupuganti, S., Roupshael, N., Anderson, E. J., Mehta, A. K.,
286 Wrammert, J., Suthar, M. S., Ahmed, R., & McElrath, M. J. (2021). Longitudinal
287 analysis shows durable and broad immune memory after SARS-CoV-2 infection
288 with persisting antibody responses and memory B and T cells. *Cell Rep Med*,
289 2(7), 100354. <https://doi.org/10.1016/j.xcrm.2021.100354>
- 290 Dong, E., Du, H., & Gardner, L. (2020). An interactive web-based dashboard to track
291 COVID-19 in real time. *Lancet Infect Dis*, 20(5), 533-534.
292 [https://doi.org/10.1016/S1473-3099\(20\)30120-1](https://doi.org/10.1016/S1473-3099(20)30120-1)
- 293 Gazit, S., Shlezinger, R., Perez, G., Lotan, R., Peretz, A., Ben-Tov, A., Cohen, D.,
294 Muhsen, K., Chodick, G., & Patalon, T. (2021). Comparing SARS-CoV-2 natural
295 immunity to vaccine-induced immunity: reinfections versus breakthrough
296 infections. *medRxiv*. <https://doi.org/10.1101/2021.08.24.21262415>
- 297 Goldberg, Y., Mandel, M., Woodbridge, Y., Fluss, R., Novikov, I., Yaari, R., Ziv, A.,
298 Freedman, L., & Huppert, A. (2021). Protection of previous SARS-CoV-2

299 infection is similar to that of BNT162b2 vaccine protection: A three-month
300 nationwide experience from Israel. *medRxiv*.

301 Hall, V. J., Foulkes, S., Charlett, A., Atti, A., Monk, E. J. M., Simmons, R., Wellington,
302 E., Cole, M. J., Saei, A., Oguti, B., Munro, K., Wallace, S., Kirwan, P. D., Shrotri,
303 M., Vusirikala, A., Rokadiya, S., Kall, M., Zambon, M., Ramsay, M., Brooks, T.,
304 Brown, C. S., Chand, M. A., Hopkins, S., & Group, S. S. (2021). SARS-CoV-2
305 infection rates of antibody-positive compared with antibody-negative health-care
306 workers in England: a large, multicentre, prospective cohort study (SIREN).
307 *Lancet*, 397(10283), 1459-1469. [https://doi.org/10.1016/S0140-6736\(21\)00675-9](https://doi.org/10.1016/S0140-6736(21)00675-9)

308 Hansen, C. H., Michlmayr, D., Gubbels, S. M., Molbak, K., & Ethelberg, S. (2021).
309 Assessment of protection against reinfection with SARS-CoV-2 among 4 million
310 PCR-tested individuals in Denmark in 2020: a population-level observational
311 study. *Lancet*, 397(10280), 1204-1212. [https://doi.org/10.1016/S0140-6736\(21\)00575-4](https://doi.org/10.1016/S0140-6736(21)00575-4)

312

313 Harvey, R. A., Rassen, J. A., Kabelac, C. A., Turenne, W., Leonard, S., Klesh, R.,
314 Meyer, W. A., 3rd, Kaufman, H. W., Anderson, S., Cohen, O., Petkov, V. I.,
315 Cronin, K. A., Van Dyke, A. L., Lowy, D. R., Sharpless, N. E., & Penberthy, L. T.
316 (2021). Association of SARS-CoV-2 Seropositive Antibody Test With Risk of
317 Future Infection. *JAMA Intern Med*, 181(5), 672-679.
318 <https://doi.org/10.1001/jamainternmed.2021.0366>

319 Jeffery-Smith, A., Iyanger, N., Williams, S. V., Chow, J. Y., Aiano, F., Hoschler, K.,
320 Lackenby, A., Ellis, J., Platt, S., Miah, S., Brown, K., Amirthalingam, G., Patel,
321 M., Ramsay, M. E., Gopal, R., Charlett, A., Ladhani, S. N., & Zambon, M. (2021).

- 322 Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care
323 homes, September and October 2020. *Euro Surveill*, 26(5).
324 <https://doi.org/10.2807/1560-7917.ES.2021.26.5.2100092>
- 325 Jin, H., Liu, J., Cui, M., & Lu, L. (2020). Novel coronavirus pneumonia emergency in
326 Zhuhai: impact and challenges. *J Hosp Infect*, 104(4), 452-453.
327 <https://doi.org/10.1016/j.jhin.2020.02.005>
- 328 Kojima, N., Roshani, A., Brobeck, M., Baca, A., & Klausner, J. D. (2021). Incidence of
329 Severe Acute Respiratory Syndrome Coronavirus-2 infection among previously
330 infected or vaccinated employees. *medRxiv*.
331 <https://doi.org/10.1101/2021.07.03.21259976>
- 332 Leidi, A., Berner, A., Roxane, D., Dubos, R., Koegler, F., Piumatti, G., Vuilleumier, N.,
333 Kaiser, L., Balavoine, J. F., Trono, D., Pittet, D., Chappuis, F., Kherad, O.,
334 Courvoisier, D., Azman, A. S., Zaballa, M. E., Guessous, I., & Stringhini, S.
335 (2021). Occupational risk of SARS-CoV-2 infection and reinfection during the
336 second pandemic surge: a cohort study. *medRxiv*.
337 <https://doi.org/10.1101/2021.08.06.21261419>
- 338 Leidi, A., Koegler, F., Dumont, R., Dubos, R., Zaballa, M. E., Piumatti, G., Coen, M.,
339 Berner, A., Darbellay Farhoumand, P., Vetter, P., Vuilleumier, N., Kaiser, L.,
340 Courvoisier, D., Azman, A. S., Guessous, I., Stringhini, S., & group, S. E.-P. s.
341 (2021). Risk of reinfection after seroconversion to SARS-CoV-2: A population-
342 based propensity-score matched cohort study. *Clin Infect Dis*.
343 <https://doi.org/10.1093/cid/ciab495>

- 344 Letizia, A. G., Ge, Y., Vangeti, S., Goforth, C., Weir, D. L., Kuzmina, N. A., Balinsky, C.
345 A., Chen, H. W., Ewing, D., Soares-Schanoski, A., George, M. C., Graham, W.
346 D., Jones, F., Bharaj, P., Lizewski, R. A., Lizewski, S. E., Marayag, J.,
347 Marjanovic, N., Miller, C. M., Mofsowitz, S., Nair, V. D., Nunez, E., Parent, D. M.,
348 Porter, C. K., Santa Ana, E., Schilling, M., Stadlbauer, D., Sugiharto, V. A.,
349 Termini, M., Sun, P., Tracy, R. P., Krammer, F., Bukreyev, A., Ramos, I., &
350 Sealfon, S. C. (2021). SARS-CoV-2 seropositivity and subsequent infection risk
351 in healthy young adults: a prospective cohort study. *Lancet Respir Med*.
352 [https://doi.org/10.1016/S2213-2600\(21\)00158-2](https://doi.org/10.1016/S2213-2600(21)00158-2)
- 353 Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C.
354 D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville,
355 J., Grimshaw, J. M., Hrobjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-
356 Wilson, E., McDonald, S., McGuinness, L. A., Stewart, L. A., Thomas, J., Tricco,
357 A. C., Welch, V. A., Whiting, P., & Moher, D. (2021). The PRISMA 2020
358 statement: an updated guideline for reporting systematic reviews. *BMJ*, 372, n71.
359 <https://doi.org/10.1136/bmj.n71>
- 360 Pilz, S., Chakeri, A., Ioannidis, J. P., Richter, L., Theiler-Schwetz, V., Trummer, C.,
361 Krause, R., & Allerberger, F. (2021). SARS-CoV-2 re-infection risk in Austria. *Eur*
362 *J Clin Invest*, 51(4), e13520. <https://doi.org/10.1111/eci.13520>
- 363 Pouwels, K. B., Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Vihta, K.-
364 D., House, T., Hay, J., Bell, J. I., Newton, J. N., Farrar, J., Crook, D., Cook,
365 D., Rourke, E., Studley, R., Peto, T., Diamond, I., Walker, A. S., & Team, C.-I.

- 366 S. (2021). Impact of Delta on viral burden and vaccine effectiveness against new
367 SARS-CoV-2 infections in the UK *Nuffield Department of Medicine*.
- 368 Qureshi, A. I., Baskett, W. I., Huang, W., Lobanova, I., Naqvi, S. H., & Shyu, C. R.
369 (2021). Re-infection with SARS-CoV-2 in Patients Undergoing Serial Laboratory
370 Testing. *Clin Infect Dis*. <https://doi.org/10.1093/cid/ciab345>
- 371 Rennert, L., & McMahan, C. (2021). Risk of SARS-CoV-2 reinfection in a university
372 student population. *Clin Infect Dis*. <https://doi.org/10.1093/cid/ciab454>
- 373 Rouse, B. T., & Sehrawat, S. (2010). Immunity and immunopathology to viruses: what
374 decides the outcome? *Nat Rev Immunol*, 10(7), 514-526.
375 <https://doi.org/10.1038/nri2802>
- 376 Sheehan, M. M., Reddy, A. J., & Rothberg, M. B. (2021). Reinfection Rates among
377 Patients who Previously Tested Positive for COVID-19: a Retrospective Cohort
378 Study. *Clin Infect Dis*. <https://doi.org/10.1093/cid/ciab234>
- 379 Shrestha, N. K., Burke, P. C., Nowacki, A. S., Terpeluk, P., & Gordon, S. M. (2021).
380 Necessity of COVID-19 vaccination in previously infected individuals. *medRxiv*.
- 381 Stephens, D. S., & McElrath, M. J. (2020). COVID-19 and the Path to Immunity. *JAMA*,
382 324(13), 1279-1281. <https://doi.org/10.1001/jama.2020.16656>
- 383 Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J.,
384 Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., Kuntz, J. L.,
385 Dunnigan, K., Odean, M. J., Hegmann, K. T., Stefanski, E., Edwards, L. J.,
386 Schaefer-Solle, N., Grant, L., Ellingson, K., Groom, H. C., Zunie, T., Thiese, M.
387 S., Ivacic, L., Wesley, M. G., Lamberte, J. M., Sun, X., Smith, M. E., Phillips, A.
388 L., Groover, K. D., Yoo, Y. M., Gerald, J., Brown, R. T., Herring, M. K., Joseph,

389 G., Beitel, S., Morrill, T. C., Mak, J., Rivers, P., Harris, K. M., Hunt, D. R., Arvay,
390 M. L., Kutty, P., Fry, A. M., & Gaglani, M. (2021). Interim Estimates of Vaccine
391 Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing
392 SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and
393 Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-
394 March 2021. *MMWR Morb Mortal Wkly Rep*, 70(13), 495-500.

395 <https://doi.org/10.15585/mmwr.mm7013e3>

396 Vitale, J., Mumoli, N., Clerici, P., De Paschale, M., Evangelista, I., Cei, M., & Mazzone,
397 A. (2021). Assessment of SARS-CoV-2 Reinfection 1 Year After Primary
398 Infection in a Population in Lombardy, Italy. *JAMA Intern Med*.

399 <https://doi.org/10.1001/jamainternmed.2021.2959>

400

401 Table. Studies through Aug 8, 2021 that show prior COVID-19 infection reduces risk for re-infection

Setting	Percent reduction in re-infection	Sample size	Follow up (months)	Reference	
Israel	94.8%	238,702	9.92 million person-months	Goldberg, MedRxiv, April 20, 2021	(Goldberg et al., 2021)
England	84.0%	25,661	Median 9.2 (IQR: 7.3-9.7)	Hall, Lancet, Apr 9, 2021	(Hall et al., 2021)
Denmark	80.5%	525,339	Maximum 10.3	Hansen, Lancet, Mar 27, 2021	(Hansen et al., 2021)
USA	100.0%	5,052	12625.2 person-months	Kojima, MedRxiv, July 8, 2021	(Kojima et al., 2021)
US Marines	82.0%	3,076	All 1.9	Letizia, Lancet Resp Med, Apr 15, 2021	(Letizia et al., 2021)
Austria	91.0%	8,900,480	Maximum 9.4	Pilz, Euro J of Clin Invest, Feb 13, 2021	(Pilz et al., 2021)
USA	84.0%	16,101	All 8.4	Rennert, Clin Inf Dis, May 16, 2021	(Rennert & McMahan, 2021)
USA	81.8%	150,325	Follow up to 9.8	Sheehan, Clin Infect Dis, Mar 15, 2021	(Sheehan et al., 2021)
USA	100.0%	52,238	Median 5.1 (IQR: 2.7-6.4)	Shrestha, MedRxiv, June 1, 2021	(Shrestha et al., 2021)
Italy	94.0%	13,496	Mean 9.3 (SD 1.4)	Vitale, JAMA IM, May 28, 2021	(Vitale et al., 2021)
Weighted average	90.4% +/- 7.65%	9,930,470			

402

403

404 Figure. PRISMA flow diagram for systematic reviews

405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437

